Abbreviations: Alb-uPA, albumin-urokinase type plasminogen activator transgene; CD31, platelet endothelial cell adhesion molecule (CD31 antigen); BCRP, breast cancer registance protein; MDR1, P-glycoprotein; MRP2, multidrug resistance associated protein 2; MRP3, multidrug resistance associated protein 3; OAT2, organic anion transporter 2; OATP1B1, organic anion transporting polypeptide 1B1; PAS, periodic acid Schiff; SAM, S-methyladenosylmethionine; ZO-1, zonula occludens-1 (tight junction protein) Summary: The ability to predict circulating human metabolites of a candidate drug before first-in-man studies are carried out would provide a clear advantage in drug development. A recent report demonstrated that while in vitro studies using human liver preparations reliably predict primary human metabolites in plasma, the predictability of secondary metabolites, formed by multiple reactions, was low, with total success rates of Ã65z. Here, we assess the use of chimeric mice with humanized liver as an animal model for the prediction of human metabolism in vivo. Metabolism studies with debrisoquine and (S)-warfarin demonstrated significantly higher concentrations of their primary human abundant metabolites in serum or plasma in chimeric mice than in control mice. Humanized chimeric mice were also capable of producing human-specific metabolites of several in-house compounds which were generated through more than one metabolism reaction. This model is closer to in vivo human physiology and therefore appears to have an advantage over in vitro systems in predicting complex metabolites in human plasma. However, prediction of human metabolites failed for other compounds which were highly metabolized in mice. Although requiring careful consideration of compound suitability, this model represents a potential tool for predicting human metabolites in combination with conventional in vitro systems.
Introduction
The ability to predict the metabolism of a new drug in humans at an early stage of drug development provides various advantages in the selection of appropriate animal species for pharmacological and toxicological studies on the basis of their metabolic similarities to humans. 1) Recent progress in the evaluation of drug safety has emphasized the importance of multiple exposure of patients to a drug's metabolites, and the necessity of adequate exposure of animal species to the human metabolites in toxicity studies. 2, 3) In February 2008, the FDA issued Guidance for Industry: for Safety Testing of Drug Metabolites 4) after formal discussions between the FDA and the pharmaceutical industry on the issue of humaǹ`m etabolites in safety testing.'' The so-called MIST guidance requires that metabolites occurring at exposures greater than 10% of the parent drug and presenting at disproportionately higher levels in humans than in any of the toxicity study animals should be subjected to additional safety evaluations. The definition and criteria of the metabolites of interest (human-specific or disproportionate metabolites) were moderated by the International Conference on Harmonization (ICH M3 (R2)), 5) e.g.,``greater than 10% of the parent drug'' has becomè`g reater than 10% of total drug-related exposure'', and Fig. 1 . Success rates of pooled human hepatocytes, liver S-9 fractions, and liver microsomes in predicting circulating human metabolites (A) Phase 1, primary, and secondary metabolites. (B) Phase 2, primary, and secondary metabolites. In addition to NADPH, reaction mixtures of S-9 fractions and microsomes were fortified with UDPGA/PAPS/SAM/acetyl coenzyme A and UDPGA as cofactors for conjugation reactions, respectively. Values above the bar represent the % success of the number of compounds that produced in vivo metabolites in each of the in vitro systems. 12) the value of 10% could be raised for drugs for which the daily administration dose is less than 10 mg. However, meeting the guidance still requires that a range of measures be taken as early as possible, including structure elucidation, synthesis of standard and bulk compounds, analytical method development, and comparative nonclinical and clinical pharmacokinetic studies on the human metabolites. [6] [7] [8] The first step in observing the MIST guidance for the pharmaceutical industry is the prediction of humanspecific or disproportionate metabolites. This is commonly done using metabolism studies with human liver preparations, and several in vitro models have been developed in the past few decades. 9, 10) Until very recently, however, no systemic analysis of success and failure rates for predicting human circulating metabolites from in vitro studies has appeared. Anderson et al. 11) reviewed 17 small nonbiologic molecules in the Lilly portfolio for which human data from both in vitro and radiolabeled metabolism studies in vivo were available. The in vitro studies were conducted using human microsomes, hepatocytes or liver slices. Results showed that the in vitro data adequately predicted the in vivo circulating metabolites for 41% of the molecules, underpredicted them in 35%, and overpredicted them in the rest (24%). The greater the number of metabolism reactions, the less accurately the in vitro data tended to predict circulating human metabolites. A second attempt with 37 Pfizer compounds and other commercially available compounds having the same data availability as the Lilly molecules using three commonly used in vitro systems, i.e., human hepatocytes, liver S-9 fractions and pooled liver microsomes, reported success rates for the in vitro systems in producing a complete circulating metabolite profile of 65%, 59% and 46%, respectively. 12) As with the Lilly molecules, success rates were significantly affected by the complexity of the metabolism: when analysis was restricted to metabolites generated through a single reaction (primary metabolites), success rates for hepatocytes, S-9 fractions and microsomes increased to 77%, 81% and 73%, respectively, but decreased to 47%, 33% and 20% for metabolites generated through more than one reaction (secondary metabolites). Similar results were obtained when these metabolites were divided into two different types: for phase 1 metabolites generated by oxidation, reduction or hydrolysis reactions, for example in hepatocytes, success rates for primary and secondary metabolites were 75% and 22%, respectively (Fig. 1) ; while for phase 2 metabolites generated by conjugation in hepatocytes, rates for primary and secondary (hydroxylation followed by glucuronidation, for example) metabolites were 73% and 30%, respectively. Similar results were obtained with liver S-9 fractions and pooled liver microsomes. These data suggest that in vitro systems using human liver preparations reliably predict human circulating metabolites generated through a single reaction regardless of the type of the reaction, i.e., phase 1 or phase 2. The lower rates for secondary metabolites were likely due to the limited access of the primary metabolites to the subsequent metabolism to generate the secondary metabolites in the in vitro environment within a limited incubation time.
Recent success in the bulk production of chimeric mice with humanized liver (for the details, see the Chimeric Mice with Humanized Liver section) has facilitated the use of this animal model in drug development. 13) Application of these chimeric mice to a wide range of drug metabolism studies has been well documented in recent reviews, including in vitro and in vivo metabolism, induction and inhibition of P450 isozymes, and excretion of given drugs. 14, 15) More recently, Yamazaki et al. 16) have reported a new application of this animal model for the evaluation of in vivo covalent binding of reactive metabolites to hepatic proteins. Since this model is closer to humans in vivo, it may be expected to overcome the draw- backs of the in vitro metabolism systems. Given the regulatory importance of circulating metabolites, as described above, we focused the present review on the ability of these chimeric mice to predict in vivo metabolites in human plasma.
Chimeric Mice with Humanized Liver
The unique ability of the adult liver to fully regenerate after injury or partial hepatectomy is well known. Rhim et al. 17) demonstrated that the rapid growth of transplanted mouse hepatocytes replicated the diseased liver of the transgenic mice caused by hepatocyte-targeted expression of the albumin-urokinase type plasminogen activator transgene (Alb-uPA). This finding has been further applied to xenogeneic hepatocyte transplantation from rats to Alb-uPA/nude mice, 18) from woodchucks to AlbuPA/Rag-2 mice 19) and from humans to Alb-uPA/Rag-2 20, 21) and Alb-uPA/SCID mice. 22) These immunotolerant recipient mice were histologically chimeric and bore parenchymal hepatocytes of the donor with biliary tract and portal structures which were considered to be primarily host-derived. 18) They were used to study the hepatocellular biology of the donor species. Further, infection of human hepatitis B and C viruses after inoculation of these chimeric mice with human hepatocytes has also been proved. Although replacement of the mouse liver by human tissue remained as high as several tens of percent, Tateno et al. 13) generated Alb-uPA/SCID chimeric mice with hepatic replacement of more than 80%, and this model is now widely used in drug development. Recently, new attempts have been made to generate chimeric mice with humanized liver by transplanting human hepatocytes to liver-deficient Fah
-/-mice 23) and NOD/Shi-scid/IL2rg -/-mice, 24) but the application of these novel models to drug development has not been reported. Thus, all data produced originally or referenced in the present review were generated using Alb-uPA/SCID chimeric mice with humanized liver. 13) We histologically examined liver of Alb-uPA/SCID chimeric mice kindly provided by PhoenixBio Co. Ltd., Hiroshima, Japan. Human hepatocytes had been seeded in the infant murine liver and grew in a nodular pattern within the framework of the entire liver. Human hepatocytes were arranged with a cobblestone-like appearance without the structure of the hepatic lobule or hepatic cord ( Fig. 2A) . Most human hepatocytes were swollen slightly, and the cytoplasm appeared to be uniformly pale and rarefied. Human hepatocytes showed diffuse intracellular accumulation of glycogen granules (PAS-positive). Some human hepatocytes occasionally showed cytoplasmic vacuoles of various sizes. On the other hand, coexistent mouse hepatocytes were damaged by uPA expression and showed diffuse atrophy, cytoplasmic vacuolation and necrosis. In addition, small or large regenerative nodules of transgene-deleted murine hepatocytes were also seen, 25) and these often displaced an entire lobe in the liver of mice with low replacement index. Serum concentration of human albumin correlated with the magnitude of replacement by human hepatocytes, and could be used as a marker for estimating the replacement index. 13) Integration of human hepatocytes into the liver architecture was evaluated by histochemistry for CD31 as an endothelial marker and ZO-1 as a tight junction localized in the bile canaliculi of hepatocytes. Sinusoids lined by a layer of endothelial cells between the human hepatocytes were sparsely detected by CD31 immunostaining (Fig. 2B) . Areas containing human hepatocytes showed networks of ZO-1-positive bile canaliculi. Bile canaliculi from individual human hepatocytes arborized extensively within the cluster of human hepatocytes. Structures considered to connect human bile canaliculi to neighboring mouse interlobular bile ducts were also observed (Fig.  2C) . To detect human transporter expression in the chimeric livers, we analyzed liver sections by immunohistochemistry using antibodies against basolateral transporters (OATP1B1, OAT2 and MRP3 (one of the efflux pumps in the bosolateral membrane)) and canalicular transporters (MRP2 and MDR1). OATP1B1 and MRP3 were exclusively expressed at the basolateral membrane of human hepatocytes. Although OAT2 was expressed over the entire human hepatocyte membrane, staining was more prominent at the basolateral membrane. Immunostaining for the canalicular transporters, including MRP2 and MDR1, showed strong expression at the apical membrane of the human hepatocytes in the same pattern as that observed with ZO-1. Double staining for OATP1B1 and MRP2 demonstrated that OATP1B1 and MRP2 were expressed in the respective sides of human hepatocytes, and that human hepatocytes maintained apical-basolateral polarity (Fig. 2D ).
Successful Metabolism Studies
Debrisoquine: Debrisoquine is extensively metabolized in humans. Formation of the major metabolite, 4-hydroxy-debrisoquine (4-OHDB), is primarily mediated by CYP2D6, 26) a polymorphic enzyme, 27) and debrisoquine has served as a common phenotyping agent for CYP2D6 since the late 1970s. Although a large number of reported clinical studies have used the urinary debrisoquine/4-OHDB ratio as a metric, 28) knowledge of its pharmacokinetics in humans is markedly limited. Sloan et al. 29) gave debrisoquine orally to four extensive metabolizers (EM) and three poor metabolizers (PM) and found that PM subjects exhibited significantly higher plasma levels of the parent drug at all time points from 1 h post-dosing. AUC0-/ of PM was 3-4 times higher than that of EM, despite the lack of any significant difference in the elimination half-lives in EM (3.0 h) and PM (3.3 h). Regarding 4-OHDB, plasma concentrations have to our knowledge been reported in only five hypertensive patients after oral dosing of debrisoquine at 10 or 20 mg. 30) Although these patients were not genotyped or phenotyped, the comparability of their plasma concentrations of unchanged drug with those of the EM group in the above report suggested that all were EM subjects. The plasma levels of 4-OHDB reached maximum at 2 h after dosing and declined with a half-life of 9.7 h. The Cmax ratio of 4-OHDB to debrisoquine was about 1.4.
The finding that debrisoquine is extensively metabolized to 4-OHDB in rats and dogs as well as in humans suggests that it is not a specific or disproportionate metabolite in humans. 31) In contrast to these species, debrisoquine is hardly metabolized by mouse liver microsomes. 32) The metabolic activity of mouse-liver Cyp2d isozymes toward debrisoquine is specifically low, in contrast to their efficient metabolism of other substrates of rat Cyp2d isozymes, such as propranolol and imipramine. Based on these characteristics, Corchero et al. 33) generated a transgenic-mouse line expressing the human CYP2D6 gene and used it to investigate the pharmacokinetic profiles of debrisoquine. After oral administration of debrisoquine hemisulfate to wild-type mice, serum concentration of the unchanged drug reached maximum at 2.5 h and then declined with a half-life of 16.5 h. In contrast, serum levels of debrisoquine in CYP2D6 homozygous humanized mice were significantly lower than in wild-type mice, and half-lives were shortened to 6.9 h. Serum levels of 4-OHDB were consistently much higher in CYP2D6 homozygous mice than in the wild type, with ratios of 4-OHDB to debrisoquine for AUC0-24 h of 2.0 in CYP2D6 homozygous mice versus 0.04 in the wild-type.
Since humanized liver of chimeric mice expresses CYP2D6 together with other human CYP isozymes, Katoh et al. 34) generated chimeric mice by transplanting hepatocytes from a 9-month-old Caucasian male to uPA ＋/＋ /SCID mice and subjected them to debrisoquine pharmacokinetic studies. Chimeric mice inherited the genotype of the donor hepatocytes. 35) The transplanted hepatocytes had been subjected to CYP2D6*3, CYP2D6*4 and CYP2D6*5 genotyping 36) and the donor was confirmed not to be a poor metabolizer. The generated chimeric mice were divided into two groups: those having a hepatic replacement index of more than 70% (High) and those having less than 10% (Low). Following oral administration of 2.0 mg/kg debrisoquine to uPA -/-/SCID mice used as the control, serum concentration of the unchanged form reached a Cmax of 306 nM at 1.6 h (Fig.  3A) . Although Cmax in the High (360 nM) and Low (250 nM) groups did not greatly differ from that in the control, elimination as reflected in the serum level in the High group seemed to be faster than that of the control. On the other hand, serum concentrations of 4-OHDB in the High group reached a Cmax of 297 nM at 1.2 h, while those in the Low and control groups remained at about one-fifth of that for the High group at the maxima (Fig.  3B ). Chimeric mice with humanized liver did not show a decrease in debrisoquine levels against the control, whereas the serum concentration of 4-OHDB was in- S-7-OH, (S)-7-hydroxywarfarin; I.S., internal standard creased significantly by transplantation. The CYP2D6 transgenic mice more closely resembled humans than the chimeric mice did in the pharmacokinetics of both debrisoquine and its metabolite. However, these transgenic mice can only be used if the test compound is known to be metabolized by CYP2D6.
(S)-Warfarin: The anticoagulant warfarin is a racemic mixture of (R)-and (S)-enantiomers. (S)-Warfarin exhibits two to five times more potent pharmacological activity than (R)-warfarin, 37) and in humans it is metabolized mainly to (S)-7-hydroxywarfarin by CYP2C9. 38, 39) When warfarin was orally administered to healthy male volunteers, the plasma concentration of (S)-warfarin reached maximum at 1 h and declined with a half-life of 24 h. 40) The plasma concentration of (S)-7-hydroxywarfarin gradually increased and reached maximum at 18 h and then declined with a half-life of 25.0 h. AUC0-/ of (S)-7-hydroxywarfarin was 13% that of (S)-warfarin.
Expression of CYP2C9 in the humanized liver of chimeric mice is similar to that of the donor hepatocytes. 41) In their in vitro metabolism study using liver microsomes from chimeric mice, Inoue and her colleagues 42) found that warfarin-7-hydroxylase activity increased with increasing hepatic replacement ratio with human hepatocytes, and was markedly inhibited by the CYP2C9 inhibitor sulfaphenazole. They then administered (S)-warfarin to chimeric mice and analyzed the parent compound and its major metabolite in plasma. Figure 4 shows HPLC chromatograms demonstrating a distinct increase in the peak corresponding to (S)-7-hydroxywarfarin in chimeric Samples were taken at 2 h after dosing in mice, and 0.5-to 24-h samples were pooled in humans. 43) 228
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mice compared with control (uPA ＋/＋ /SCID) mice. Compound A: Compound A, a drug candidate under development at Astellas Pharma Inc. with a molecular weight of 396.4, 43) is metabolized to H1, H2, H3 and H4 in humans in vivo (Fig. 5) . LC/MS/MS analyses suggested that H1 is generated by conjugation of an aliphatic alcohol with glucuronic acid and hydroxylation of the azulene ring. H2 is formed by hydroxylation at the azulene ring and subsequent sulfate conjugation of the aromatic alcohol. H3 and H4 are direct glucuronide conjugates of Compound A. In metabolism studies in animals, H2 H3, H4 and H5 (another direct glucuronide conjugate) were found in the plasma of monkeys, whereas H1 was not found in the plasma of mice, rats, hamsters, guinea pigs, rabbits, dogs or monkeys, and only a trace amount was seen in marmosets. Moreover, H1
was not found in in vitro studies using human liver microsomes and hepatocytes. After oral administration of Compound A to ICR mice as a control, the main peak in plasma at 2 h after dosing was attributed to the parent compound, and peaks of metabolites H2, H3, H4 and H5 were also detected (Fig. 6A) . In the plasma of chimeric mice obtained at the same time after dosing, H1 was detected together with the parent compound and metabolite peaks found in the ICR mouse plasma (Fig. 6B) . This metabolism pattern resembled that in human plasma obtained in the first-in-man study (samples between 0.5 and 24 h were pooled) (Fig. 6C) . Thus, H1, the secondary metabolite of Compound A, was found only in chimeric mice and humans in vivo. Further, in a mass balance study in the humanized chimeric mice using 14 C-Compound A, 1.62% of the orally administered radioactivity was ex- creted as H1 into urine within 24 h.
Compound B: Compound B is another investigational drug under development at Astellas Pharma Inc., and has a molecular weight of 407.8.
43)
After incubation of 14 C-Compound B with human hepatocytes, almost equal amounts of H6 and H7 were found in the reaction mixture. H6 is a secondary metabolite formed by Nmethylation of a pyrrolopyridine ring and sulfate conjugation of an aliphatic alcohol, while H7 is a primary metabolite formed by sulfate conjugation of the same aliphatic alcohol (Fig. 7) . Although H7 was detected in the plasma of rats, rabbits and monkeys after oral dosing of Compound B, H6 was not found in the plasma of any of these animals; neither H7 nor H6 was detected in mouse plasma (Fig. 8A) . H6 was therefore presumed to be a human-specific circulating metabolite. On oral administration of Compound B to chimeric mice with humanized liver, both this metabolite and H7 were detected in plasma (Fig. 8B) . Analyses of plasma samples obtained in the first-in-man study, recently conducted in healthy male volunteers, revealed that both H6 and H7 were also present in human plasma (Fig. 8C) . Although the existence of the human-specific metabolite of Compound A in plasma was retrospectively predicted, to our knowledge this episode represents the first successful prediction of the formation of a circulating human metabolite in vivo using chimeric mice with humanized liver before the conduct of the first-in-man study. Fig. 9 . Major metabolic pathways of amosulalol in mice and humans M-3 sulfate, the major metabolite in humans, was found as one of the minor metabolites in mice.
45)

Metabolism Studies with Unexpected Outcomes
Amosulalol: The combined a-and b-blocker amosulalol hydrochloride is extensively metabolized in rats, dogs and monkeys, giving five to six metabolites. 44) This compound is also highly metabolized in mice, with 22% of the dose excreted into urine as M-2 glucuronide and 1.4% as M-3 sulfate. 45) In contrast to that in experimental animals, metabolism in humans is rather unique in that only M-3 sulfate is found as the urinary metabolite (12.7% of the dose). 46) The major routes of metabolism therefore differ between mice and humans in both phase 1 and phase 2 metabolism (Fig. 9 ). An in vitro correlation study using liver microsomes from 16 different donors suggested that amosulalol was mainly metabolized by CYP3A4. 47) We selected amosulalol as a model compound because the liver of chimeric mice express both CYP3A4 35) and human sulfotransferases. 48) In preliminary experiments, we incubated amosulalol with mouse and human microsomes with an NADPHgenerating system and confirmed that the major primary metabolites were M-2 and M-3, respectively. When amosulalol was incubated with mouse and human hepatocytes, M-2 glucuronide and M-3 sulfate were found as the predominant in vitro metabolites, respectively. Amosulalol hydrochloride was then administered orally to humanized chimeric mice with a different hepatic replacement index (max. À80%) and uPA ＋/＋ /SCID mice as a control group. The control mice excreted M-2 glucuronide into urine as the major metabolite and M-3 sulfate as a minor metabolite. In chimeric mice, in contrast, no significant increase in M-3 sulfate was observed with the increased hepatic replacement index, and M-2 glucuronide remained the major urinary metabolite. From these results, no further studies on circulating metabolites of amosulalol were conducted.
Compound X: Kitamura et al. 49) selected their inhouse drug candidate, Compound X, as a model drug for evaluation of chimeric mice. The purpose of their study was not only to predict in vivo metabolism in humans, but also to evaluate the impact of the metabolic activity of the remaining murine hepatocytes and extrahepatic organs of the host animals. In vitro studies using 14 C-labeled Compound X indicated that this compound was metabolized to a limited extent by human hepatocytes, giving small peaks corresponding to M-1, M-2, M-1 glucuronide and M-2 glucuronide on HPLC radiochromatograms. In contrast, Compound X was well metabolized by mouse hepatocytes and microsomal preparations from mouse small intestine, giving more than ten metabolite peaks, including the four human metabolites described above. Following oral administration of 10 mg/kg 14 C-labeled Compound X, various metabolites, including M-1, M-1 glucuronide and M-2 glucuronide, were found in the serum of control mice (uPA ＋/＋ /SCID). In the humanized chimeric mice, in contrast, the serum metabolite profile was closely similar to that of the control mice, and no significant increases in the peaks of M-1, M-1 glucuronide or M-2 glucuronide were found.
In addition, Kitamura et al. 49) conducted a similar metabolism study with Compound Y, which is hardly metabolized by mouse or human hepatocytes in vitro. After oral administration of 3 mg/kg of 14 C-labeled Compound Y, HPLC radiochromatograms showed two small peaks of plasma metabolites in the humanized chimeric mice but not in the control mice. These metabolites were derived through two-step metabolism reactions, i.e. they are secondary metabolites (personal communication), and the authors are expecting to find these circulating metabolites in humans in a future first-in-man study.
Assessment of Chimeric Mice as a Tool for Prediction
In vitro studies with human liver preparations reliably predict primary metabolites in human plasma with a success rate of 73%-81%. 12) 4-OHDB and (S)-7-hydroxywarfarin, the respective major metabolites of debrisoquine and (S)-warfarin, are primary metabolites generated by a single hydroxylation step and were detected in vitro using human liver microsomes. 50, 51) Chimeric mice with humanized liver therefore appear to offer few advantages over in vitro studies in predicting human metabolites for these drugs. Nevertheless, these cases are the first examples in which serum or plasma levels of hu- In metabolism studies of Compound A using chimeric mice, the human-specific metabolite H1 was detected in the humanized mouse plasma. This metabolite was formed by hydroxylation of the aromatic ring and conjugation of aliphatic alcohol with glucuronic acid. In the case of Compound B, the human-specific metabolite H6 was found; it was formed by N-methylation of a pyrrolopyridine ring and sulfate conjugation of aliphatic alcohol. As described in the Introduction, the predictive value of in vitro systems which use human liver preparations for secondary metabolites are markedly low.
12)
The lower rate of formation of secondary metabolites may be attributed to the limited access of compounds to sequential metabolism in vitro. In the reaction mixture, the amounts of metabolizing enzymes and cofactors relative to drug-related materials are not necessarily optimized, and these enzymes and cofactors decline significantly even in a given incubation period. 52, 53) In contrast, human hepatocytes in chimeric mice are probably maintained under physiological conditions which are closer to those in humans in vivo and are continuously exposed to drugrelated materials by systemic blood circulation, as supported by the presence of sinusoids on CD31 immunostaining of the liver (Fig. 2B) . Any estimate of the predictive value of chimeric mice for circulating human metabolites from the limited number of examples in this review is difficult. Nevertheless, based on the physiological advantages of this method, a better rate of success in predicting secondary metabolites than with in vitro systems may be expected.
After being metabolized, drug-related materials are in part effluxed out from hepatocytes into the blood and bile by transporters localized at the sinusoidal and canalicular membranes, respectively. 54) In in vitro metabolism systems, all generated metabolites are mixed in the incubation media, and special devices such as sandwich-cultured hepatocytes are necessary to distinguish biliary from circulating metabolites. 55) In the liver of chimeric mice, various sinusoidal and canalicular membrane transporters were expressed in the respective membranes of human hepatocytes, suggesting vectorial efflux of given drugs and their metabolites into blood and bile (Fig. 2D) . Some metabolites generated in hepatocytes might therefore be directly excreted into bile and thus would not appear in the chimeric mouse plasma, thereby avoiding the overprediction of circulating human metabolites.
Although the prediction of human metabolites using chimeric mice with humanized liver has been successful for several compounds, the same methods produced unexpected outcomes for several other compounds. Even in chimeric mice with a high hepatic replacement index, metabolism profiles of these compounds were closely similar to those in the control mice. This phenomenon was probably due to the co-existing mouse hepatocytes and, in part, extrahepatic metabolism in chimeric mice. 49) Coexistent mouse hepatocytes were damaged by uPA expression, but appeared to maintain their metabolic activity as judged from the metabolism of several drugs by uPA ＋/＋ /SCID mice used as a control. In addition, regenerative nodules of transgene-deleted murine hepatocytes might also be present; 25) if so, these probably exerted the metabolic activities of normal liver. Meanwhile, mouse intestine expressing Cyp3a isozymes should be considered an important extrahepatic metabolism organ. 56) In the physiological pharmacokinetic model of chimeric mice (Fig. 10) , hepatic elimination of the administered drug can be expressed by the following equation based on clearance concepts: 57 58) fB is a common value for human and mouse hepatocytes. Human hepatocytes integrate into the liver of chimeric mice in a different manner from host hepatocytes and do not construct a homogeneous architecture. Thus, the ratio of Qhuman to Qhuman＋Qmouse is not necessarily equal to the hepatic replacement index. However, the larger the Fig. 11 . Comparative hepatic clearances of 168 compounds in mice and humans in vitro using liver microsomal preparations Male mouse and mixed human liver microsomes were used. Data were obtained with a substrate concentration of 0.2 mM and protein concentration of 0.2 mg protein/mL. Clearances for the five model compounds described in the text are provided in the inserted table. 43) hepatic replacement, the greater the Qhuman/Qmouse value becomes. Chimeric mice with a higher replacement index should therefore allow for the better prediction of human metabolites. Other factors governing the predictability are CLHint, human and CLHint, mouse, and these depend on the nature of the test compounds used.
In the case of amosulalol, pharmacokinetic analyses demonstrated that in vivo total clearance in ICR mice was 10.7 L/h/kg, which exceeded the hepatic blood flow, while that in humans was 0.1 L/h/kg. 45, 59) Compound X was reportedly well metabolized in mice, but metabolized to only a limited extent in humans in vitro. For these drugs with high clearance in mice and low clearance in humans, the above equation could be approximated to:
CLH, chimeric mouse ＝f BCLHint, human ＋Q mouse (Qhuman:fBCLHint, human, Qmouse9fBCLHint, mouse)
Similarly, chimeric mice with a higher replacement index should be used, because formation of mouse metabolites of drugs with high clearance in mice is governed by Qmouse. Drug candidates with diverse chemical structures synthesized in the chemical laboratories of Astellas Pharma Inc. were subjected to metabolism screening in vitro using mouse and human liver microsomes, and intrinsic hepatic clearances were compared (Fig. 11) . Of the 168 compounds, 87% exhibited equal or higher hepatic intrinsic clearance in mice than in humans. The five model compounds appearing in this review were also subjected to the same screening system, and their intrinsic hepatic clearances are listed in the table inserted in Figure 11 .
Reaction conditions were not optimized for the individual compounds, and values were obtained by single-timepoint analyses with fixed substrate and protein concentrations. Moreover, the respective clearances mainly represent the rates of CYP-mediated phase 1 metabolism, and do not represent conjugation reactions and nonmicrosomal metabolism. Nevertheless, this rough estimate may provide some hints in elucidating the applicability of compounds to the humanized animal model. Intrinsic clearances of the five compounds in mice varied with a range of 65.8-484.2 mL/min/kg, whereas the clearances in humans was relatively low and fell in a much narrower range. It is worth noting that human metabolites of interest were also present in the serum or plasma of control mice as minor metabolites in the cases of debrisoquine, (S)-warfarin and amosulalol. Intrinsic clearances of debrisoquine and (S)-warfarin in mice were relatively small, and might reflect significant increases in the circulating human metabolites 4-OHDB and (S)-7-hydroxywarfarin, respectively, by transplantation of human hepatocytes. In contrast, intrinsic clearance of amosulalol in mice was relatively high, and hepatic clearance in chimeric mice in vivo likely exceeded Qmouse, as occurred in intact mice. 45) Humanization of the mouse liver did not result in a significant increase in the human metabolite M-3 sulfate, probably because Qmouse was much larger than the hepatic clearance of human hepatocytes in vivo. Hepatic intrinsic clearances of Compound A and Compound B in mice were also high, and these compounds may in this sense be categorized similarly to amosulalol. In fact, peaks of the human circulating metabolites H1 and H6 were relatively small in chimeric mice [see Figs. 6(i) and 8(i), respectively]. However, these human-specific metabolites could be easily distinguished from other metabolites because they were completely absent in the control mouse plasma, as confirmed by sensitive product ion scanning [Figs. 6(ii) and 8(ii)]. We therefore suggest that chimeric mice with humanized liver can predict human-specific metabolites even when the drug of interest is highly metabolized in mice. However, prediction of the significant increase of disproportionate human metabolites of drugs with high clearance in mice and low clearance in humans may be difficult. Very recently, Bateman et al. 60) also reported predictive metabolism studies using chimeric mice with humanized liver for four model compounds which were known to generate human-specific or predominant metabolites. They succeeded in predicting human metabolism with lamotrigine, MRK-A and diclofenac. In the case of propafenone, however, the metabolite profile in the humanized mice was similar to that in the control animals, suggesting that propafenone might be categorized among the drugs readily metabolized in mice and moderately metabolized in humans, such as amosulalol.
Conclusion
Given the importance of circulating human metabolites in the development of new therapeutic chemical entities, we assessed the ability of chimeric mice with humanized liver to predict in vivo human metabolism based on reported and in-house data. Histochemical examination of these mice livers revealed that various sinusoidal and canalicular membrane transporters were expressed in the respective cell membranes of human hepatocytes. This structure suggested the vectorial efflux of given drugs and their metabolites into blood and bile, which would thereby avoid the overprediction of human metabolites in the circulating blood. Metabolism studies with chimeric mice using debrisoquine and (S)-warfarin demonstrated that transplantation of human hepatocytes significantly increased the levels of primary metabolites in the serum or plasma of host animals. Humanized chimeric mice were also capable of producing humanspecific metabolites of Compound A and Compound B, and probably Compound Y, which were generated through more than one metabolism reaction. Although the limited number of examples hampers the drawing of conclusions, chimeric mice with humanized liver appear to have an advantage over in vitro systems in predicting complex metabolites, because this model is physiologically closer to that of humans in vivo.
In general, most chemicals are metabolized faster in mice than in humans. Because the successful prediction of circulating human metabolites may be hindered when a test drug is highly metabolized in mice but also has metabolites common to humans, chimeric mice with as high a hepatic replacement index as possible should be used. Evaluation of the applicability of a candidate drug based on its in vitro metabolism data using mouse and human liver preparations is also recommended. Humanized chimeric mice alone cannot mitigate the risk of disproportionate circulating metabolites when development is conducted in accordance with the MIST guidance, but their potential advantages can be used to supplement in vitro metabolism data. Although the selection of suitable compounds is necessary, these chimeric mice are considered a potential tool in predicting circulating human metabolites in combination with conventional in vitro systems, and may increase the overall rate of success.
